To validate a previously developed efficacy prediction model for CD19 CAR-T in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), highlighting its significance in improving patient selection for therapy.
Key Findings:
The median follow-up was 14.6 months.
The C-index for the 5-index model was 0.767, indicating good predictive performance, suggesting reliable risk stratification.
Significant differences in PFS (P < 0.0001) and OS (P = 0.0007) were observed across different risk groups.
The model outperformed traditional prognostic indices such as IPI and R-IPI.
Interpretation:
The 5-index risk model demonstrated robust predictive ability in a real-world setting, providing a reliable basis for personalized treatment decisions in Chinese DLBCL patients undergoing CAR-T, potentially improving clinical outcomes.
Limitations:
The study is retrospective and may be subject to biases inherent in such designs.
The cohort is limited to Chinese patients, which may affect generalizability to other populations, and the sample size may limit the statistical power of the findings.
Conclusion:
The study validates the 5-index model for predicting outcomes in R/R DLBCL patients receiving CAR-T therapy, highlighting its potential for guiding treatment decisions.
